Rechipharm contracted to make lidocaine formulation for IUD-related pain

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Initial public offering

Rechipharm contracted to make novel lidocaine formulation
Recipharm AB will manufacture commercial supplies of a topical formulation of the anaesthetic lidocaine called Shact that is soon to be launched by developer Pharmanest AB.

The new contract –terms of which were not disclosed – will see the Swedish contract manufacturing organisation’s (CMO) semi-solid products unit make Shact – which is used to alleviate discomfort and pain during IUD insertion - at its facility in Karlskoga.

Recipharm will manufacture Shact along with a proprietary application device developed to simplify topical application in the cervix and uterus in a long term deal that will extend to any country in which the drug is launched.

The manufacturing contract is the first Recipharm has announced since it completed its initial public offering on the NASDAQOMX exchange on April 3.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars